TrialCancer discovery2019
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
Naval Daver et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
366 papers cite itlatest 60 shown
this paperpooled ittrialcites it